DFX Intelligence
Venture Capital Intelligence
Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.
Companies / Gilgamesh Pharma Inc.
Gilgamesh Pharma Inc.
Stage unknownNew York, NYPharmaceuticals
Facts
Financing history
5 rounds
- Mar 27, 2026Form D equity offering · $2.3M (form d sold) · 3 investorsFact SEC EDGAR Form D data sets (quarterly) · “Gilgamesh Pharma Inc. filed Form D: $2,250,000 sold of $15,000,000, Pharmaceuticals”
- Mar 24, 2026Series A · $60.0M (disclosed)Satori Neuro (lead)Prime Movers Lab (participant)Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS) · “Gilgamesh Pharma Closes Oversubscribed $60 Million Series A to Develop Next Generation Neuropsychiatric Therapies”
- Mar 9, 2026Form D equity offering · $60.0M (form d sold) · 40 investorsFact SEC EDGAR Form D data sets (quarterly) · “Gilgamesh Pharma Inc. filed Form D: $60,000,000 sold of $60,000,000, Pharmaceuticals”
- Feb 4, 2026Form D equity offering · $0 (form d sold) · 8 investorsFact SEC EDGAR Form D data sets (quarterly) · “Gilgamesh Pharma Inc. filed Form D: no sales yet of $4,366,118, Pharmaceuticals”
- Jan 2, 2026Form D equity offering · $6.1M (form d sold) · 9 investorsFact SEC EDGAR Form D data sets (quarterly) · “Gilgamesh Pharma Inc. filed Form D: $6,090,946 sold of $6,090,946, Pharmaceuticals”
Investors on record
2 edges
- Prime Movers Lab round, participant Fact prnewswire.com
- Satori Neuro round, lead Fact prnewswire.com
People
2 officers, 4 directors
- Andrew Kruegel Executive Officer/Director sec.gov
- Jonathan Sporn Executive Officer/Director sec.gov
- Robert Berman Director Fact
- AMY Kruse Director Fact
- Phil Skolnick Director Fact
- Zia Huque Director Fact
Timeline
5
- Mar 31, 2026Gilgamesh Pharma Inc. filed Form D: $2,250,000 sold of $15,000,000, PharmaceuticalsForm D filed Fact SEC EDGAR Form D data sets (quarterly)
- Mar 24, 2026Gilgamesh Pharma announced Series A of $60,000,000, led by Satori NeuroRound announced Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS)
- Mar 24, 2026Gilgamesh Pharma Inc. filed Form D: $60,000,000 sold of $60,000,000, PharmaceuticalsForm D filed Fact SEC EDGAR Form D data sets (quarterly)
- Feb 4, 2026Gilgamesh Pharma Inc. filed Form D: $6,090,946 sold of $6,090,946, PharmaceuticalsForm D filed Fact SEC EDGAR Form D data sets (quarterly)
- Feb 4, 2026Gilgamesh Pharma Inc. filed Form D: no sales yet of $4,366,118, PharmaceuticalsForm D filed Fact SEC EDGAR Form D data sets (quarterly)
Evidence
51 observations
Every observation on this company
- Entity type: Corporation Mar 31, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Entity type: Corporation Mar 24, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Entity type: Corporation Feb 4, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Form D industry group: Pharmaceuticals Mar 31, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Form D industry group: Pharmaceuticals Mar 24, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Form D industry group: Pharmaceuticals Feb 4, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Amendment: false Mar 31, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Amendment: false Mar 24, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Amendment: false Feb 4, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Revenue range (Form D): Decline to Disclose Mar 31, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Revenue range (Form D): Decline to Disclose Mar 24, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Revenue range (Form D): Decline to Disclose Feb 4, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Incorporated: withinFiveYears Mar 31, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Incorporated: withinFiveYears Mar 24, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Incorporated: withinFiveYears Feb 4, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Jurisdiction: DELAWARE Mar 31, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Jurisdiction: DELAWARE Mar 24, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Jurisdiction: DELAWARE Feb 4, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Amount sold (Form D): $2.3M Mar 31, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Amount sold (Form D): $60.0M Mar 24, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Amount sold (Form D): $6.1M Feb 4, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Amount sold (Form D): $0 Feb 4, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Offering amount (Form D): $15.0M Mar 31, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Offering amount (Form D): $60.0M Mar 24, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Offering amount (Form D): $6.1M Feb 4, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Offering amount (Form D): $4.4M Feb 4, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Exemptions: 06b Mar 31, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Exemptions: 06b Mar 24, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Exemptions: 06b Feb 4, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- First sale: 2026-03-27 Mar 31, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- First sale: 2026-03-09 Mar 24, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- First sale: 2026-01-02 Feb 4, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Investors (Form D): 3 Mar 31, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Investors (Form D): 40 Mar 24, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Investors (Form D): 9 Feb 4, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Investors (Form D): 8 Feb 4, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Minimum investment (Form D): 50,000 Mar 31, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Minimum investment (Form D): 50,000 Mar 24, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Minimum investment (Form D): 27,597 Feb 4, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Minimum investment (Form D): 27 Feb 4, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Securities offered: option Mar 31, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Securities offered: equity Mar 24, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Securities offered: equity Feb 4, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Securities offered: option Feb 4, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Office address: 113 UNIVERSITY PLACE, SUITE 1019, NEW YORK, NY, 10003 Mar 31, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Office address: 113 UNIVERSITY PLACE, SUITE 1019, NEW YORK, NY, 10003 Mar 24, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Office address: 113 UNIVERSITY PLACE, SUITE 1019, NEW YORK, NY, 10003 Feb 4, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Round announced: Series A $60,000,000 Mar 24, 2026 Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS)
- Year of incorporation: 2025 Mar 31, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Year of incorporation: 2025 Mar 24, 2026 Fact SEC EDGAR Form D data sets (quarterly)
- Year of incorporation: 2025 Feb 4, 2026 Fact SEC EDGAR Form D data sets (quarterly)